Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s): CLAZF

Healthcare

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.

TSXV:CLAS.H - Post by User

Claritas Pharmaceuticals Inc

Bullboard Posts

Post by Montevialeon Dec 06, 2017 11:19am

242 Views

Post# 27101077

Has Aphria Liquidated their position in Kalytera?

A lot of specualtion these days about Aphria's investment in Kalytera. I posted back on November 9th that I believe Aphira liquidated their shares in Kalytera. The reason why I believe this to be true is that prior to Aphria's AGM on October 25th Kalytera was listed on Aphria's Investor Deck as an investment. After the AGM meeting it was quietly removed from the investor deck pdf filed on Aphria's website. Why would Aphria remove it from their investor deck if they hadnt liquidated their shares?

Also, because Aphria held less than 10% of Kalytera they dont have to disclose it at the time of liquidation. However, watch for Aphria's next quarterly release coming out in January because it will tell the rest of the story.

M

Bullboard Posts

Barrick Gold employees detained in Mali amid ongoing dispute